Tuberculous pericarditis differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 22: Line 22:
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
! rowspan="4"  style="background: #4479BA; color: #FFFFFF; text-align: center;|Diseases
! rowspan="4"  style="background: #4479BA; color: #FFFFFF; text-align: center;|Diseases
|
| colspan="6" rowspan="1"  style="background: #4479BA; color: #FFFFFF; text-align: center;|'''Clinical manifestations'''
| colspan="6" rowspan="1"  style="background: #4479BA; color: #FFFFFF; text-align: center;|'''Clinical manifestations'''
|
|
Line 28: Line 29:
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;|Additional findings
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;|Additional findings
|-
|-
| rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;|'''History'''
| colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;|'''Symptoms'''
| colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;|'''Symptoms'''
! colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination
! colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination
Line 50: Line 52:
|-
|-
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
! colspan="17" |Constrictive pericarditis
! colspan="18" |Constrictive pericarditis
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Tuberculosis
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Tuberculosis
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 71: Line 74:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Idiopathic/Viral
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Idiopathic/Viral
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 89: Line 93:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Post cardiac surgery
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Post cardiac surgery
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 107: Line 112:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Post radiation
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Post radiation
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 125: Line 131:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Connective tissue disease
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Connective tissue disease
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 143: Line 150:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Malignancy
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Malignancy
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 161: Line 169:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Mesothelioma]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Mesothelioma]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 179: Line 188:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Chronic [[renal failure]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Chronic [[renal failure]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 197: Line 207:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Asbestosis
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Asbestosis
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 214: Line 225:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
! colspan="17" |Restrictive cardiomyopathy
! colspan="18" |Restrictive cardiomyopathy
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Amyloidosis
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Amyloidosis
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 235: Line 247:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Sarcoidosis
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Sarcoidosis
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 253: Line 266:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Hemochromatosis
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Hemochromatosis
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 271: Line 285:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Sclerodema
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Sclerodema
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 289: Line 304:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Endomyocardial fibrosis
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Endomyocardial fibrosis
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 307: Line 323:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Carcinoid heart disease
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Carcinoid heart disease
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 325: Line 342:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Post radiation
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Post radiation
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 343: Line 361:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Diabetic cardiomyopathy
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Diabetic cardiomyopathy
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 361: Line 380:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Hurler
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Hurler
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 379: Line 399:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Gaucher
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Gaucher
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 397: Line 418:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Fabry
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Fabry
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 415: Line 437:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Wegener
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Wegener
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 433: Line 456:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Metastatic malignancies
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Metastatic malignancies
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |

Revision as of 15:30, 28 February 2020

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview


Differentiating [Disease name] from other Diseases

[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].

OR

[Disease name] must be differentiated from [differential dx1], [differential dx2], and [differential dx3].

OR

As [disease name] manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype. [Subtype name 1] must be differentiated from other diseases that cause [clinical feature 1], such as [differential dx1] and [differential dx2]. In contrast, [subtype name 2] must be differentiated from other diseases that cause [clinical feature 2], such as [differential dx3] and [differential dx4].

Differentiating [disease name] from other diseases on the basis of [symptom 1], [symptom 2], and [symptom 3]

On the basis [symptom 1], [symptom 2], and [symptom 3], [disease name] must be differentiated from [disease 1], [disease 2], [disease 3], [disease 4], [disease 5], and [disease 6].

Diseases Clinical manifestations Para-clinical findings Gold standard Additional findings
History Symptoms Physical examination
Lab Findings Imaging Histopathology
Chest pain Fever Cough Edema/Ascites JVP Heart/Lung sounds Hepatosplenomegaly Lab 1 Lab 2 Lab 3 CT Scan MRI Echo/Sono
Constrictive pericarditis
Tuberculosis
Idiopathic/Viral
Post cardiac surgery
Post radiation
Connective tissue disease
Malignancy
Mesothelioma
Chronic renal failure
Asbestosis
Restrictive cardiomyopathy
Amyloidosis
Sarcoidosis
Hemochromatosis
Sclerodema
Endomyocardial fibrosis
Carcinoid heart disease
Post radiation
Diabetic cardiomyopathy
Hurler
Gaucher
Fabry
Wegener
Metastatic malignancies

References

Template:WH Template:WS